The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Heteroaryl compounds and uses thereof

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

Inhibitors of bruton's tyrosine kinase

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on at least one Raf protein kinase. In certain aspects and embodiments, the described compounds are active in inhibiting proliferation of a Ras mutant cell line. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of B-Raf V600E mutant protein kinase, including melanoma, glioma, glioblastoma multiforme, pilocytic astrocytoma, colorectal cancer, thyroid cancer, lung cancer, ovarian cancer, prostate cancer, liver cancer, gallbladder cancer, gastrointestinal stromal tumors, biliary tract cancer, and cholangiocarcinoma. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of c-Raf-1 protein kinase, including acute pain, chronic pain or polycystic kidney disease.

Compounds and methods for kinase modulation, and indications therefor

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors

The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

2,4-pyrimidinediamine compounds and their uses

The invention provides a novel class of compounds of formula 1, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf

Compounds and compositions as protein kinase inhibitors

The present invention relates to compounds of Formula (1), or pharmaceutically acceptable salts thereof and their pharmaceutical compositions, wherein variables are as defined herein, which are useful as modulators of the activity of lysophosphatidic acid (LPA).

Compositions and methods for modulating lpa receptors

The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R2, R3, R4 and R5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors

La presente invention porte sur des composes de formule (1), ou des sels pharmaceutiquement acceptables de ceux-ci, et sur leurs compositions pharmaceutiques, dans laquelle formule les variables sont telles que definies dans la description. Les composes sont utiles comme modulateurs de l'activite de l'acide lysophosphatidique (LPA).

Compositions et procédés pour la modulation de récepteurs au lpa

L'invention porte sur une nouvelle classe de composes de la formule 1, sur des compositions pharmaceutiques comportant de tels composes et sur des procedes d'utilisation de tels composes pour traiter ou prevenir des maladies ou des troubles associes a une activite kinase anormale ou deregulee, en particulier des maladies ou des troubles qui entrainent une activation anormale de B-Raf.

Yongping Xie

Papers

Compounds and compositions as protein kinase inhibitors

Compositions and methods for modulating lpa receptors

N-(pyridin-2-yl)sulfonamides and compositions thereof as protein kinase inhibitors

Compositions et procédés pour la modulation de récepteurs au lpa

Composés et compositions en tant qu'inhibiteurs de protéine kinase